| Small Lymphocytic Lymphoma
Jaypirca vs Venclexta
Side-by-side clinical, coverage, and cost comparison for small lymphocytic lymphoma.Deep comparison between: Jaypirca vs Venclexta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVenclexta has a higher rate of injection site reactions vs Jaypirca based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Venclexta but not Jaypirca, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Jaypirca
Venclexta
At A Glance
Oral
Once daily
BTK inhibitor
Oral
Once daily
BCL-2 inhibitor
Indications
- Mantle cell lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Leukemia, Myelocytic, Acute
Dosing
Mantle cell lymphoma 200 mg orally once daily until disease progression or unacceptable toxicity; swallow tablets whole with water, with or without food.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 200 mg orally once daily until disease progression or unacceptable toxicity; swallow tablets whole with water, with or without food.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma 5-week ramp-up starting at 20 mg, increasing to 400 mg orally once daily; used as monotherapy or in combination with acalabrutinib, obinutuzumab, or rituximab.
Leukemia, Myelocytic, Acute 3- or 4-day ramp-up to 400 mg orally once daily in combination with azacitidine or decitabine, or 600 mg orally once daily in combination with low-dose cytarabine, each in 28-day cycles.
Contraindications
—
- Concomitant use with strong CYP3A inhibitors at initiation and during the ramp-up phase in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma due to increased risk of tumor lysis syndrome
Adverse Reactions
Most common (>=30%) Decreased neutrophil count, decreased hemoglobin, decreased leukocytes, fatigue, decreased platelets, decreased lymphocyte count, calcium decreased
Serious Pneumonia, COVID-19, sepsis, febrile neutropenia, hemorrhage, pleural effusion
Most common (>=20%) in CLL/SLL Neutropenia, thrombocytopenia, anemia, diarrhea, nausea, upper respiratory tract infection, cough, musculoskeletal pain, fatigue, edema
Most common (>=30%) in AML Nausea, diarrhea, thrombocytopenia, constipation, neutropenia, febrile neutropenia, fatigue, vomiting, edema, pyrexia, pneumonia, dyspnea, hemorrhage, anemia, rash, abdominal pain, sepsis, musculoskeletal pain, dizziness, cough, oropharyngeal pain, hypotension
Serious Tumor lysis syndrome, febrile neutropenia, pneumonia, sepsis, hemorrhage
Pharmacology
Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK, a signaling protein of the B-cell antigen receptor and cytokine receptor pathways; it binds wild-type BTK and BTK harboring C481 mutations to inhibit BTK kinase activity and suppress malignant B-cell proliferation.
BCL-2 inhibitor; venetoclax is a selective, orally bioavailable small-molecule that restores apoptosis by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins like BIM and triggering mitochondrial outer membrane permeabilization and activation of caspases.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Jaypirca
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
Venclexta
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Jaypirca
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (1/8) · Qty limit (2/8)
Venclexta
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Jaypirca
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Venclexta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Chronic Lymphocytic Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Venclexta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JaypircaView full Jaypirca profile
VenclextaView full Venclexta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.